B
73.64
-1.12 (-1.50%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | BridgeBio Pharma, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
1.3
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | -3.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 1.25 |
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 4.97% |
| 机构持股比例 | 98.14% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 110.00 (Cantor Fitzgerald, 49.38%) | 购买 |
| 中 | 87.00 (18.14%) | |
| 低 | 71.00 (Raymond James, -3.59%) | 购买 |
| 平均值 | 88.70 (20.45%) | |
| 总计 | 10 购买 | |
| 平均价格@调整类型 | 62.11 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Wells Fargo | 11 Nov 2025 | 84.00 (14.07%) | 购买 | 66.58 |
| JP Morgan | 07 Nov 2025 | 77.00 (4.56%) | 购买 | 61.80 |
| HC Wainwright & Co. | 03 Nov 2025 | 90.00 (22.22%) | 购买 | 61.98 |
| 29 Oct 2025 | 90.00 (22.22%) | 购买 | 66.62 | |
| Goldman Sachs | 31 Oct 2025 | 100.00 (35.80%) | 购买 | 62.64 |
| Cantor Fitzgerald | 30 Oct 2025 | 110.00 (49.38%) | 购买 | 63.37 |
| Piper Sandler | 30 Oct 2025 | 98.00 (33.08%) | 购买 | 63.37 |
| Raymond James | 30 Oct 2025 | 71.00 (-3.59%) | 购买 | 63.37 |
| 21 Oct 2025 | 59.00 (-19.88%) | 购买 | 54.36 | |
| TD Cowen | 30 Oct 2025 | 95.00 (29.01%) | 购买 | 63.37 |
| Truist Securities | 30 Oct 2025 | 80.00 (8.64%) | 购买 | 63.37 |
| UBS | 12 Sep 2025 | 82.00 (11.35%) | 购买 | 51.21 |
| 显示更多 | ||||
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合